Microviable Therapeutics Seeks Over €5 Million to Secure its Clinical Trial

Microviable Therapeutics, is seeking financing to continue growing. The Spanish biotech company that develops oral medicines based on products derived from the microbiota expects to be able to open a financing round of more than five million euros soon to advance its research toward the clinical phase, according to Claudio Hidalgo, CEO of Microviable Therapeutics, who explains that it is a company forecast.

The company expects to raise new funds that will ensure that it reaches a clinical trial for its product aimed at infectious diseases. It also hopes to advance in the development of two products: one for oncological diseases and the other for autoimmune diseases.

With the aim of leading the development of new products, the Asturian company has signed David Ríos as the new technical director. The new addition to Microviable Therapeutics is a Doctor in Biology from the University of Oviedo and has a Master’s in Food Biotechnology and a Bachelor’s degree in Biology from the same university. During his doctorate, Ríos focused on the study of metabolic interactions between human intestinal microbial populations, developing different techniques in various international centers.

Ríos developed his postdoctoral work at the University of California San Diego (United States), focusing on the immune response of the intestinal mucosa to DNA damage. Subsequently, he joined the Micalis Institute (France) to study these interactions in the context of the development of the immune system in neonates. The technical director will also be in charge of relations with public institutions and hospitals, collaborating with the research and development (R&D) area.

Read more about Microviable Therapeutics and find the latest financial news of the day with the Born2Invest mobile app.

Microviable Therapeutics has signed David Ríos as technical director

Microviable Therapeutics’ most advanced product is MVT-201, which has been evaluated in the preclinical phase with positive results and is a unique biologic based on whole intestinal microbiota for various indications. The company is confident that it will enter the clinical phase very soon.

The product is obtained by purification and does not require propagation, maintaining the high concentration, diversity, and richness of microorganisms like the original microbiota of a healthy person. Thanks to Microviable Therapeutics’ technology, the company can obtain purified human microbiota in viable conditions for use as a therapeutic.

Microviable Therapeutics emerged as a spin-off of Ipla-Csic in 2016, focused on the development of therapeutic technologies and products derived from microbiota. Technological development, together with the extensive collection of bacterial cultures, has allowed the Spanish company to generate products for the complete purified microbiota and personalized microbial consortia for different diseases.

Hildago has a PhD in Biology from the University of Oviedo, where he previously graduated in Biology and obtained a Master’s in Biotechnology. He developed his doctorate in the field of probiotics and microbial genetics, completing numerous international stays in public and private research centers, including a four-year postdoctoral stay at  North Carolina State University  (Raleigh, United States).

In the direction, they accompany Hidalgo Rafael Permuy, who is responsible for business development and is a founding partner of Healthsens, Neurostech, Criogene, and Asturhealth, and Noelia Martínez, head of research and development (R&D), with a degree in Biology and a PhD by the University of Oviedo.

In 2022, the company closed a round of financing of €1.5 million led by the Madrid medical group Immunomet, a company specialized in intolerances and intestinal dysbiosis, with experience in the clinical field. He is currently the main investor in the company.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.